Syner-G BioPharma Group
Tom Puthiaparampil Ph.D has extensive work experience in the pharmaceutical and biotech industry. Tom currently serves as the Country Head - India for Syner-G BioPharma Group, starting in March 2021. Prior to this, they held the position of Vice President Special Projects at Sami-Sabinsa Group Limited from December 2017 to February 2021.
Before joining Sami-Sabinsa, Tom worked at Anthem Biosciences Private Limited as the Director - Chemistry & Head - Project Management from January 2007 to April 2017. Tom also gained significant experience at Syngene International Limited, where they served as a Senior Scientific Manager from May 1995 to December 2006.
Tom's career began at Cipla in January 1989, where they worked as an R&D Officer until April 1995. Overall, Tom Puthiaparampil Ph.D has demonstrated their expertise and leadership in various roles and has a strong background in project management and scientific research.
Tom Puthiaparampil Ph.D's education history includes the following:
- Tom obtained a Ph.D. degree from an unspecified institution.
- Tom completed Grade X at AKJM Kanjirapally.
- Tom earned a Doctor of Philosophy (Ph.D.) degree in Synthetic Organic Chemistry from the School of Chemical Sciences at Mahatma Gandhi University.
- Tom obtained an MS degree in Organic Chemistry from St. Berchmans College Changanachery.
- Tom holds a BSc degree in Chemistry from St. Dominics College Kanjirapally.
Additionally, Tom Puthiaparampil Ph.D has a certification as a member of the ACS until 2017 from Anthem Biosciences Private Limited.
This person is not in any teams
This person is not in any offices
Syner-G BioPharma Group
Syner-G BioPharma Group provides in-depth expertise across the three key elements of Chemistry, Manufacturing, and Controls (CMC): Regulatory Services, Technical Development, and Quality/IT. We call this CMC 360™. We also provide medical writing services, with expertise in authoring a variety of regulatory documents across a wide range of therapeutic areas and in all phases of development. Our regulatory affairs services include the development and implementation of global regulatory strategic plans, regulatory agency meeting support, and electronic submissions to regulatory authorities around the world. We have the skill set and experience to guide your prime asset through any development challenges and along the ever-changing maze of regulatory filing pathways, to a position of full compliance, and high quality. Our expertise spans small molecules, peptides, oligonucleotides, biologics, monoclonal antibodies, antibody-drug conjugates, and cell and gene therapy products.